Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT01769196 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

544

Enrollment

INDUSTRY

Sponsor class

Stopped The Study was terminated due to lack of efficacy.

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: Simtuzumab
DRUG: Simtuzumab placebo

Sponsor

Gilead Sciences